secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-021205
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Finch Therapeutics dismisses Deloitte, appoints Wolf & Company as new auditor effective May 12, 2023
--------------------------------------------------------------------------------

- Audit Committee approved dismissal of Deloitte and engagement of Wolf & Company, effective May 12, 2023.
- Decision driven by goal of reducing ongoing costs related to annual audit.
- Deloitte's reports for 2021 and 2022 contained no adverse opinion except a going concern explanatory paragraph.
- Material weakness in internal controls as of Dec 31, 2019 was remediated as of Dec 31, 2021.
- No disagreements or reportable events with Deloitte during 2021, 2022, and through May 8, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000095017023021205/0000950170-23-021205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000095017023021205/fnch-20230508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer